Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

Inclusion Criteria: * Patients with hematologic malignancy, lymphoma or other HIV-associated malignancy are eligible provided these criteria are met: * The malignancy is in complete remission or very good partial remission, defined as a significant reduction of disease with therapy and no evidence for continued tumor growth in the case of lymphoma or solid tumors * Highly active antiretroviral therapy (HAART) is initiated within one month of hematopoietic cell transplant * Viral load has decreased by \>= 1.5 logs or viral load \< 5000 copies/ml plasma on HAART therapy * CD4 count is allowed to be \> 100 cells/ul * HIV infected patients without malignancy who have failed HAART are eligible provided that these criteria are met: * They have been treated with more than one regimen of HAART for a total of at least 6 months duration * The viral load is \< 50 copies/ml plasma * The CD4 count \< 100 cells/ul * DONOR: Human leukocyte antigen (HLA) genotypically/phenotypically identical donor; if more than one HLA-identical sibling is available, priority will be given to donors matched for cytomegalovirus (CMV) status, ABO titer, and sex * Peripheral blood stem cells will be collected from donors greater than 12 years of age * Bone marrow will be collected from donors less than 12 years of age * DONOR: HLA phenotypically identical unrelated donor; match grades allowed: * Match grade 1: Matched at allele level for HLA-A, B, C, DRB1, and DQB1 * Match grade 2.1:…